Zimeta is a pyrazolone anti-inflammatory drug with a novel mechanism of action. Zimeta is under development for the control of pyrexia (fever) in horses.

Fever is a common condition in nearly three-quarter of a million horses per year and can result in anorexia and lethargy.1 If prolonged, fever may result in debilitating outcomes such as muscle wasting and tissue breakdown.  Recovery can be prolonged with loss of training and delayed competition. There are currently no approved veterinary drugs for the management of fever in horses, therefore practitioners must rely on off-label use of nonsteroidal anti-inflammatory drugs, which has limitations.2,3

Zimeta (dipyrone injection)

The application for Zimeta is currently under review at the FDA Center for Veterinary Medicine (CVM).  Approval and launch of the drug is expected in 2018.

Zimeta (dipyrone oral gel)

In December 2017, Kindred Bio announced positive results from the pivotal study of Zimeta oral for fever in horses.  The company anticipates submitting the Effectiveness technical section of the New Animal Drug Application in early 2018, and the Safety and Chemistry, Manufacturing and Controls technical sections in the first half of 2018, assuming the data are supportive of approval.

1 The Economic Impact of the Horse Industry on the United States, 2005, American Horse Council Foundation (n=18,648 U.S. horse owners/industry suppliers).

2 Epub: Cook VL andBlikslager AT. The use of nonsteroidal anti-inflammatory drugs in critically ill horses.  J Vet Emerg Crit Care (San Antonio). 2015 Jan-Feb; 25(1):76-88.

3 Marshall JF and Blikslager AT.  The effect of nonsteroidal anti-inflammatory drugs on the equine intestine.  Equine Vet J Suppl. 2011 Aug; 39:140-144.